Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Rule 38.5 - Pfizer INC

10 Nov 2015 11:16

RNS Number : 1870F
Morgan Stanley Capital Services LLC
10 November 2015
Β 

ο»Ώ

Β 

Β FORM 38.5(a)

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(a)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANELΒ ACT,Β 1997, TAKEOVER Β RULES,Β 2013

Β 

DEALINGS BY CONNECTEDΒ EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARYΒ STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

Β 

Β 

1. KEYΒ INFORMATION

Β Name of exempt market-maker

Morgan Stanley Capital Services LLC

Β Company dealt in

PFIZER INC

Β Class of relevant security to which the dealings being disclosed relate (Note 1)

US$0.05 COMMON STOCK

Β Date of dealing

09 NOVEMBER 2015

Β 

Β 

2. DEALINGSΒ (NoteΒ 2)

Β 

(a) PurchasesΒ andΒ sales

Β Total number of relevant secuities accquired

Β Highest price paid (Note 3)

Β Lowest price paid (Note 3)

Β Β 53,867

Β 33.9300 USD

Β 33.3900 USD

Β 

Β Total number of relevant secuities disposed

Β Highest price paid (Note 3)

Β Lowest price paid (Note 3)

Β Β 109,621

Β 33.9300 USD

Β 33.3900 USD

Β 

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Β Product name, e.g. CFD

Β Nature of transaction

(Note 4)

Β Number of relevant securities

(Note 5)

Β Price per unit

Β CFD

Β LONG

Β 32

Β 33.5700 USD

Β CFD

Β LONG

Β 33,850

Β 33.6031 USD

Β CFD

Β LONG

Β 536

Β 33.6108 USD

Β CFD

Β LONG

Β 2,800

Β 33.6171 USD

Β CFD

Β LONG

Β 587

Β 33.6245 USD

Β CFD

Β LONG

Β 1,700

Β 33.6300 USD

Β CFD

Β LONG

Β 1

Β 33.6336 USD

Β CFD

Β LONG

Β 13,800

Β 33.6400 USD

Β CFD

Β LONG

Β 776

Β 33.6500 USD

Β CFD

Β LONG

Β 200

Β 33.6500 USD

Β CFD

Β LONG

Β 200

Β 33.6750 USD

Β CFD

Β LONG

Β 14,800

Β 33.6851 USD

Β CFD

Β LONG

Β 200

Β 33.6900 USD

Β CFD

Β LONG

Β 3,017

Β 33.7170 USD

Β CFD

Β LONG

Β 1,925

Β 33.7340 USD

Β CFD

Β LONG

Β 9,415

Β 33.7425 USD

Β CFD

Β LONG

Β 400

Β 33.7525 USD

Β CFD

Β LONG

Β 3,500

Β 33.7628 USD

Β CFD

Β LONG

Β 600

Β 33.7700 USD

Β CFD

Β LONG

Β 1,400

Β 33.7714 USD

Β CFD

Β SHORT

Β 2,800

Β 33.4528 USD

Β CFD

Β SHORT

Β 3,800

Β 33.4712 USD

Β CFD

Β SHORT

Β 5

Β 33.5000 USD

Β CFD

Β SHORT

Β 2

Β 33.5000 USD

Β CFD

Β SHORT

Β 200

Β 33.5000 USD

Β CFD

Β SHORT

Β 291

Β 33.5147 USD

Β CFD

Β SHORT

Β 12

Β 33.5147 USD

Β CFD

Β SHORT

Β 6

Β 33.5147 USD

Β CFD

Β SHORT

Β 92

Β 33.5147 USD

Β CFD

Β SHORT

Β 1,373

Β 33.5147 USD

Β CFD

Β SHORT

Β 3,592

Β 33.5285 USD

Β CFD

Β SHORT

Β 1,000

Β 33.5344 USD

Β CFD

Β SHORT

Β 4,200

Β 33.5402 USD

Β CFD

Β SHORT

Β 32

Β 33.5429 USD

Β CFD

Β SHORT

Β 275

Β 33.5512 USD

Β CFD

Β SHORT

Β 151

Β 33.5512 USD

Β CFD

Β SHORT

Β 10,000

Β 33.5618 USD

Β CFD

Β SHORT

Β 4

Β 33.5778 USD

Β CFD

Β SHORT

Β 8

Β 33.5778 USD

Β CFD

Β SHORT

Β 600

Β 33.5833 USD

Β CFD

Β SHORT

Β 96

Β 33.5905 USD

Β CFD

Β SHORT

Β 237

Β 33.5905 USD

Β CFD

Β SHORT

Β 200

Β 33.6001 USD

Β CFD

Β SHORT

Β 3,600

Β 33.6006 USD

Β CFD

Β SHORT

Β 1,679

Β 33.6100 USD

Β CFD

Β SHORT

Β 3,100

Β 33.6310 USD

Β CFD

Β SHORT

Β 300

Β 33.6433 USD

Β CFD

Β SHORT

Β 2,900

Β 33.6492 USD

Β CFD

Β SHORT

Β 3,900

Β 33.6791 USD

Β CFD

Β SHORT

Β 3,266

Β 33.6855 USD

Β CFD

Β SHORT

Β 497

Β 33.7372 USD

Β CFD

Β SHORT

Β 145

Β 33.7407 USD

Β CFD

Β SHORT

Β 1,200

Β 33.7533 USD

Β CFD

Β SHORT

Β 200

Β 33.8050 USD

Β 

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Β Product name, eg call option

Β Writing, selling, purchasing, varying etc

Β Number of securities to which the option relates (Note 5)

Β Exercise Price

Β Type, e.g American, European etc

Β Expiry Date

Β Option money paid/received per unit (Note 3)

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β 

(ii) Exercising

Β 

Β Product name, eg call option

Β Number of securities

Β Exercise price per unit (Note 3)

Β N/A

Β N/A

Β N/A

Β 

Β 

3. OTHER INFORMATION

Β 

Agreements, arrangements or understandings relating to options or derivatives

Β 

Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β Date of disclosure

Β 10 NOVEMBER 2015

Β Contact Name

Craig Horsley

Β Telephone Number

+44(141) 245 7736

Β Name of offeree/offeror with which connected

ALLERGAN PLC

Nature of connection (Note 6)

Advisory

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEBMBBTMBBBBTA
Date   Source Headline
16th May 201411:29 amRNSForm 8.5 (EPT/RI)
16th May 201411:27 amRNSForm 8 (DD) - [Pfizer Inc]
16th May 201411:18 amRNSForm 8.3 - Pfizer Inc
16th May 201411:13 amRNSForm 8.5 (EPT/RI)
16th May 201411:12 amRNSForm 8.5 (EPT/NON-RI)
16th May 201411:00 amRNSRule 2.10 Announcement
16th May 201410:31 amRNSForm 8.3 - Pfizer Inc
16th May 20149:18 amRNSRule 2.10 Announcement
16th May 20147:00 amPRNForm 8.3 - Pfizer Inc.
15th May 20145:52 pmRNSForm 8.3 - Pfizer Inc
15th May 20145:50 pmRNSForm 8.3 - AstraZeneca Plc
15th May 20145:16 pmRNSForm 8 (DD) - [Pfizer Inc]
15th May 20145:14 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
15th May 20143:52 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:50 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:33 pmRNSForm 8.5 (EPT/NON-RI) Amendment
15th May 20143:32 pmRNSForm 8.3 - [Pfizer/Astrazeneca]
15th May 20143:28 pmBUSForm 8.3 - Pfizer Inc
15th May 20143:26 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
15th May 20143:22 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:10 pmRNSForm 8.5 (EPT/NON-RI) Amendment
15th May 20143:02 pmBUSForm 8.3 - Pfizer Inc.
15th May 20142:50 pmRNSForm 8.3 - [PFIZER INC]
15th May 20142:42 pmBUSForm 8.3 - Pfizer Inc
15th May 20142:29 pmRNSForm 8.3 - [Pfizer Inc]
15th May 20141:55 pmRNSForm 8.5 (EPT/RI) Pfizer Inc. Amendment
15th May 20141:36 pmRNSForm 8.3 - Pfizer Inc
15th May 20141:34 pmRNSForm 8.3 - AstraZeneca Plc
15th May 20141:26 pmRNSForm 8.3 - Pfizer Inc
15th May 20141:24 pmRNSForm 8 (DD) - Pfizer Inc.
15th May 20141:23 pmRNSForm 8.3 - AstraZeneca Plc
15th May 201412:57 pmBUSForm 8.3 - Pfizer Inc.
15th May 201412:39 pmRNSForm 8.3 - [AstraZeneca Plc]
15th May 201412:22 pmRNSForm 8.3 - [Pfizer Inc]
15th May 201412:15 pmRNSForm 8.5 (EPT/NON-RI)
15th May 201412:10 pmRNSForm 8.5 (EPT/RI)
15th May 201412:09 pmBUSForm 8.3 - Pfizer Inc
15th May 201411:55 amRNSForm 8.3 - Pfizer, Inc.
15th May 201411:34 amRNSForm 8 (DD) - [Pfizer Inc]
15th May 201411:32 amRNSForm 8.5 (EPT/RI)
15th May 201411:27 amRNSForm 8.5 (EPT/RI) Pfizer Inc
15th May 201411:04 amRNSForm 8.3 - Pfizer Inc
15th May 201411:00 amRNSForm 8.5 (EPT/RI) - Pfizer
15th May 201411:00 amRNSRule 2.10 Announcement
15th May 20149:39 amRNSRule 2.10 Announcement
14th May 20144:48 pmRNSForm 8.3 - Replacement - Pfizer Inc
14th May 20143:31 pmRNSForm 8.3 - Pfizer Inc
14th May 20143:26 pmRNSForm 8.3 - Pfizer Inc.
14th May 20143:26 pmRNSForm 8.3 - Pfizer Inc
14th May 20143:23 pmRNSForm 8.3 - AstraZeneca Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.